Project Co-Ordinator, LEX Diagnostics

Engagement snapshot

Product type: Point-of-Care PCR
Environment: Medical Devices
Cross-functional teams: R&D + Engineering + Operations
Product stage: R&D

CONTEXT

LEX Diagnostics is a UK-based molecular diagnostics company developing ultra-fast PCR-based point-of-care diagnostic systems. The products are designed to deliver laboratory-quality clinical results within minutes during patient appointments, enabling faster clinical decision-making in urgent care, primary care and similar healthcare settings. Product development operated within strict scientific, regulatory and engineering constraints typical of medical device innovation.

MY ROLE

I supported R&D and product development teams by improving how work was structured, tracked and coordinated across a complex scientific environment. My focus was on increasing delivery visibility, defining decision criteria and ensuring processes and tooling reflected the realities of diagnostic product development rather than generic project management frameworks.

KEY CONTRIBUTIONS

Sep 2021Commenced
Project Co-Ordinator — Medical Diagnostics. Brought greater structure and execution visibility to multidisciplinary teams developing ultra-fast point-of-care molecular diagnostic systems.
M01Structured
Built and maintained the end-to-end project plan for the R&D medical-device programme, and set up a toolchain that read plan, schedule and budget together so progress and change were visible in one place.
M02Enabled
Introduced fit-for-purpose tooling and delivery workflows that gave R&D, engineering and operations teams shared visibility, coordination and accountability where there had been little.
M03Translated
Acted as the link between scientific, engineering and operational stakeholders, turning development needs into practical planning, reporting and decision criteria.
M04Aligned
Worked closely with heads of function to track progress and assess change, mapping how activities interrelated — their costs, timescales and knock-on effects on the wider development programme.
M05Supported
Aligned day-to-day planning and tracking with the regulatory, scientific and engineering realities of molecular diagnostics, keeping concurrent product-development activity structured and moving.

PRODUCT PRINCIPLE

Structure should support science, not constrain it.

Introduced practical delivery processes and decision frameworks that enabled multidisciplinary teams to move faster without adding unnecessary project overhead.

IMPACT

Clearer workflows, decision criteria and planning practices gave R&D, engineering and operations a shared view of where the point-of-care PCR platform actually stood. In a regulated medical device environment the binding constraint is evidence rather than speed, so the value of that structure was predictability: validation was something the plan accounted for rather than something the schedule met by surprise.